Peptides DB
Research-centric peptide and protocol reference hub

Semax vs SS-31

Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team

Semax: Research use — not FDA-approvedSS-31: Research use — not FDA-approved

A data-driven comparison of Semax and SS-31 (also searched as SS-31 vs Semax) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

Semax centers on neuro, while SS-31 leans toward healing. On indexed research, SS-31 is ahead (Semax: 12 studies, Human clinical; SS-31: 37, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • •Semax is strongest for neuro; SS-31 for healing.
  • •Evidence: Semax Human clinical (12 studies) vs SS-31 Human evidence (37).
  • •Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

SemaxSS-31

At a glance

SemaxHuman clinical

Neuroprotective | Cognitive enhancement

Strongest: NeuroStudies: 12Level: Well Studied
SS-31Human evidence

Mitochondrial protection | Heart and neuro health

Strongest: HealingStudies: 37Level: Preclinical

Semax vs SS-31: side-by-side

MetricSemaxSS-31
ClassNeuroMetabolic
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman clinicalHuman evidence
Studies indexed1237
Research levelWell StudiedPreclinical
Strongest effectNeuro & moodHealing & recovery
Healing & recovery2.04.0▲
Muscle & body comp0.02.0▲
Metabolic & appetite0.03.0▲
Neuro & mood4.0▲4.0▲
Sleep & circadian0.01.0▲
Inflammation & immune3.0▲3.0▲
Skin & aesthetics0.01.0▲

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertySemaxSS-31
MechanismACTH(4–10) analog; neuroprotective / nootropicCardiolipin binding to stabilize mitochondrial membrane
RouteIntranasal (research use)Subcutaneous injection

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Semax?

Semax is a synthetic peptide derived from the adrenocorticotropic hormone (ACTH) that has been investigated for its potential neuroprotective and cognitive-enhancing effects. Research suggests that Semax may influence various biological pathways, including neuroinflammation and intracellular calcium dynamics.

Full Semax profile, mechanism & studies →

What is SS-31?

SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.

Full SS-31 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingSS-314.0/5 effect signal
MuscleSS-312.0/5 effect signal
MetabolicSS-313.0/5 effect signal
NeuroEvenBoth ~4.0/5
SleepSS-311.0/5 effect signal
InflammationEvenBoth ~3.0/5
SkinSS-311.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack Semax and SS-31?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

Semax vs SS-31: side effects

Semax

No community-reported effects logged yet.

SS-31

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

Semax has 12 approved studies indexed (Human clinical), and SS-31 has 37 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is Semax or SS-31 better?

It depends on your goal. Semax is strongest for neuro; SS-31 for healing. SS-31 has more indexed studies (37). See the goal-by-goal breakdown above.

Is Semax or SS-31 better for weight loss?

SS-31 shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is Semax or SS-31 better for muscle?

SS-31 leads on the muscle & body-composition axis (2.0/5).

Which has more research, Semax or SS-31?

Semax has 12 approved studies indexed (Human clinical); SS-31 has 37 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack Semax and SS-31?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of Semax vs SS-31?

Semax: no community-reported effects logged yet. SS-31: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is Semax or SS-31 FDA-approved?

Semax is a research-use compound and is not FDA-approved. SS-31 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is SS-31 better than Semax?

For healing, SS-31 has the edge; for neuro, Semax does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Semax and SS-31 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.